logo

SYNH(Delisted)

Syneos Health·NASDAQ
--
--(--)

Key Stats

0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000

About SYNH

Syneos Health, Inc.

A company that provides Phase I to IV clinical development services for the biopharmaceutical and medical device industries

--
08/13/2010
11/07/2014
NASDAQ Stock Exchange
28,768
12-31
Common stock
1030 Sync Street, Morrisville, North Carolina , 27560-5468
--
Syneos Health, Inc., a Delaware corporation incorporated on August 13, 2010. The company is a leading global contract research organization based on revenue and focuses on Phase 1 to Phase 4 clinical development services for the biopharmaceutical and medical device industries. The company provides customers with highly differentiated therapeutic orientation and expertise, especially in intractable diseases such as the central nervous system and tumors. The Company has been providing clinical development services in complex environments and has provided a proprietary, actionable approach to clinical trials through its trusted process approach.

Company Financials

EPS

SYNH has released its 2023 Q1 earnings. EPS was reported at 0.75, versus the expected 0.66, beating expectations. The chart below visualizes how SYNH has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SYNH has released its 2023 Q2 earnings report, with revenue of 1.37B, reflecting a YoY change of 0.39%, and net profit of 793.00K, showing a YoY change of -98.98%. The Sankey diagram below clearly presents SYNH's revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime

No Data